Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuo Ma

Showing results (241-250 of 253) with videos related to

Pageof 26
Sort By:
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Pageof 26

Showing results (241-250 of 253) with videos related to

Sort By:
Pageof 26
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Pageof 26